Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24891256 | 0.98 | HSD11B1 (0.46) | HSD11B1SMN1; SMN2ALDH1A1ACHEGNAI3 | |
| SCHEMBL13548814 | 0.97 | SMN1; SMN2 (0.45) | HSD11B1SMN1; SMN2ALDH1A1ACHEGNAI3 | |
| SCHEMBL6921678 | 0.87 | SMN1; SMN2 (0.48) | HSD11B1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL22819552 | 0.87 | SMN1; SMN2 (0.48) | HSD11B1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL13848576 | 0.86 | HTR7 (0.41) | HSD11B1SMN1; SMN2ALDH1A1GNAI3GNAO1 | |
| SCHEMBL13848547 | 0.86 | HTR7 (0.41) | HSD11B1SMN1; SMN2ALDH1A1GNAI3GNAO1 | |
| SCHEMBL8369139 | 0.86 | HTR7 (0.41) | HSD11B1SMN1; SMN2ALDH1A1GNAI3GNAO1 | |
| SCHEMBL17547032 | 0.86 | HTR7 (0.41) | HSD11B1SMN1; SMN2ALDH1A1GNAI3GNAO1 | |
| SCHEMBL19117547 | 0.86 | HTR7 (0.41) | HSD11B1SMN1; SMN2ALDH1A1GNAI3GNAO1 | |
| SCHEMBL11919055 | 0.82 | GNAI3 (0.52) | HSD11B1SMN1; SMN2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790744-B2 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6743777-B1 | TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | EGFR, ERBB2, ERBB3 | HSD11B1 1083/4885SMN1; SMN2 4810/4885ALDH1A1 3309/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HSD11B1 290/4885SMN1; SMN2 4499/4885ALDH1A1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.